Home
 
SHEN QI



RESEARCH

Observation of Clinical Effects of Shenqifuzheng Injection Combined with Bozhi Glycopeptide and Chemotherapy in Treating Aged Lung Cancer Patients

Source:
Wang De-he, Zhou Lian-hui, Chang Chun, SHAO Nan. Observation of Clinical Effects of Shenqifuzheng Injection Combined with Bozhi Glycopeptide and Chemotherapy in Treating Aged Lung Cancer Patients. Yi Xue Zong Shu. 2013, 19(4): 733-735.

To observe clinical efficacy of Shenqifuzheng injection combined with Bozhi glycopeptide in treating aged lung cancer patients. Seventy four lung cancer patients diagnosed on their initial visit and treatment were chosen, and randomly divided into 3 groups: chemotherapy alone group (control group) of 21 cases, Shenqifuzheng injection combined with chemotherapy (single drug treatment) group of 25 cases, and Shenqifuzheng injection combined with Bozhi glycopeptide and chemotherapy (combined treatment) group of 28 cases. Curative effect and the improvement of clinical symptoms were observed, peripheral blood immune function was detected and Kamofsky score of life quality was calculated. The difference in the short-term effect, the life quality Kamofsky score and clinical symptoms improvement among the three groups had statistical significance (P<0.05). The CD4, CDs, CD4/CD8, NK in peripheral blood lymphocytes and positive cells percentage of natural killer cells were decreased significantly after chemotherapy in the control group. While the same indexes in treatment group with Shenqifuzheng injection and Bozhi glycopeptide and chemotherapy improved obviously (P<0.05). Shenqifuzheng injection combined with Bozhi glycopeptide and chemotherapy can relieve adverse reaction in treating aged lung cancer patients. The combined treatment could also enhance the quality of life and immune function and reduce complications, and thus is worthy of application in clinical settings.



Effects of Shenqi Fuzheng injection on the invasiveness of cells and expression of Tenascin -C in human gastric cancer MGC- 803 cells

Source:
Ma Junwei, Song Yongchun, Zhang Yong, Jia Yong, Dang Chengxue, Hou Junmin. Effects of Shenqi Fuzheng injection on the invasiveness of cells and expression of Tenascin -C in human gastric cancer MGC- 803 cells. Xian Dai Zhong Liu Yi Xue. 2013, 21(2): 263-266.

To investigate the effects of Shenqi Fuzheng injection on the invasiveness of cells and expressions of Tenascin-C (Tn-C) in human gastric cancer MGC-803 cells in rats, which were injected with different dosages of Shenqi Fuzheng injection (0.04g/m1, 0.08g/ml and O. 16g/ml) for 1 week. Matrigel TM test was performed to detect invasion ability of cells, and RT-PCR was used to check Tn-C mRNA expression. In treated groups, invasiveness of cells was most significant (the inhibit ratio was 34.7% in 0.16g/ml group). The expressions of Tenascin-C were lower than those of the control. There was significant difference between the high concentration group and the control. The expressions of Tenascin-C are down-regulated when gastric cancer MGC-803 cells were treated with Shenqi Fuzheng injection at high concentration, therefore the invasiveness of gastric tumors maybe reduced.



Observation on the influence of Shenqi-Fuzheng injection on T-lymphocyte subsets, NKcell and the leukocyte of the patients with advanced gastric cancer

Source :
Yin Lili, Jiang Chaoyong. Observation on the influence of Shenqi-Fuzheng injection on T-lymphocyte subsets, NKcell and the leukocyte of the patients with advanced gastric cancer. Guo Ji Zhong Yi Zhong Yao Za Zhi. 2013, 35(1): 22-24.

To explore the long term efficacy, immunodulary effect, and toxicity of Shenqi-Fuzheng injection in advanced gastric cancer patients in combination with chemotherapy; 53 patients with advanced gastric cancer were randomly divided into an treatment group (26 cases) and a control group (27 cases). All patients were treated in the oncology department of the Chinese People’s Liberation Army 264th Hospital during 2010.1~2012.6. The treatment group accepted SP chemotherapy plus Shenqi-Fuzheng injection and the control group were treated with SP chemotherapy only. After 2 cycles of chemotherapy the term efficacy, cellular immune function index, and adverse reactions were observed. The objective response rate (RR) between the treatment group and the control group had no difference (X2=0.024, P>0.05). After 2 cycles of treatment, CD3+ (64.09±7.59)%, CD4+ (44.17±6.09)%, CD8+ (27.60±7.64)%, CD4+/CD8+ (1.63±0.66) and NK(28.07±7.28)% in the observation group were higher than the control group [accordingly (54.64±6.39)%, (35.01±6.05)%, (24.29±7.41)%, (1.30±0.72), (25.06±7.24)%, (P<0.05) ]. The incidence of leukocyte decline in the observation group was 19.23%, and 44.44% in the control group. There difference was significant (P<0.05). Shenqi-Fuzheng injection plus SP chemotherapy can improve cellular immune function, tolerance to chemotherapy and reduce toxicity in patients with advanced gastric cancer.



Effect of Shenqi Fuzheng Injection combined with chemotherapy in treatment of advanced non small cell lung cancer clinical observation

Source:
Qiao Shulin. Effect of Shenqi Fuzheng Injection combined with chemotherapy in treatment of advanced non small cell lung cancer clinical observation. Zhong Guo Shi Yong Yi Yao. 2012, 7(34): 25-26.

To investigate the effect of Shenqi Fuzheng Injection in combination with chemotherapy in the treatment of advanced non-small cell lung cancer 60 patients with advanced non-small cell lung cancer were randomly divided into a treatment group or control group. The treatment group was treated by Shenqi Fuzheng Injection combined with chemotherapy, and the control group with chemotherapy alone. Treatments were continual over 2 cycles. The effect of Shenqi Fuzheng Injection combined with chemotherapy group vs the chemotherapy group alone showed no significant difference, but in reducing toxicity and side effects of chemotherapy, such as gastrointestinal reaction and leukopenia was superior to the chemotherapy alone group (P<0. 05). The effect of Shenqi Fuzheng Injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer can improve the quality of life of patients, reduce the toxic side effects of chemotherapeutic agents, and enhance immunity.



Clinical observation of the Shenqi Fuzheng injection on the response to chemotherapy in advanced lung cancer patients

Source:
Jiang Haiyan. Clinical observation of the Shenqi Fuzheng injection on the response to chemotherapy in advanced lung cancer patients. Zhong Yi Lin Chuang Yan Jiu. 2012, 4(14): 11-12.

To observe the effects on quality of life of Shenqi Fuzheng injection plus chemotherapy for advanced lung cancer patients 36 patients with advanced lung cancer were given the Shenqi Fuzheng injection plus chemotherapy for treatment and compared with 30 patients receiving chemotherapy alone. In the treatment group; symptoms of fatigue, anorexia, and nausea and vomiting were lower versus the control group. Also, the occurrence of leukopenia and thrombocytopenia in the treatment group was lower than that of the control group. Shenqi Fuzheng injection plus chemotherapy for advanced lung cancer can reduce drug toxicity, improve the patient’s fatigue, loss of appetite, gastrointestinal symptoms and improve the quality of life of patients.

 
CopyRight 2012 - ICOP